Endurance Tech remains a Buy recommendation by Citi, yet the target price is revised down to Rs 2,900 due to demand concerns. The financial services firm Fortis Healthcare expects an EBITDA margin of 22-25% by FY26. Jefferies predicts a 74% growth potential for Aavas Financiers, setting a target price at Rs 1,875. However, Morgan Stanley expresses caution and prefers Aptus and Home First Finance over Aavas Financiers.